Literature DB >> 12126092

Assessment of myocardial washout of Tc-99m-sestamibi in patients with chronic heart failure: comparison with normal control.

Shin-ichiro Kumita1, Yoshihiko Seino, Keiichi Cho, Hidenobu Nakajo, Masahiro Toba, Yoshimitsu Fukushima, Noriake Okamoto, Teruo Takano, Tatsuo Kumazaki.   

Abstract

BACKGROUND: In contrast to 201TlCl, 99mTc-sestamibi shows very slow myocardial clearance after its initial myocardial uptake. In the present study, myocardial washout of 99mTc-sestamibi was calculated in patients with non-ischemic chronic heart failure (CHF) and compared with biventricular parameters obtained from first-pass and ECG-gated myocardial perfusion SPECT data. METHODS AND
RESULTS: After administration of 99mTc-sestamibi, 25 patients with CHF and 8 normal controls (NC) were examined by ECG-gated myocardial perfusion SPECT and planar data acquisition in the early and delayed (interval of 3 hours) phase. Left ventricular ejection fraction (LVEF, %), peak filling rate (PFR, sec(-1)), end-diastolic volume (LVEDV, ml) and end-systolic volume (LVESV, ml) were automatically calculated from the ECG-gated SPECT data. Myocardial washout rates over 3 hours were calculated from the early and delayed planar images. Myocardial washout rates in the CHF group (39.6+/-5.2%) were significantly higher than those in the NC group (31.2+/-5.5%, p < 0.01). The myocardial washout rates for the 33 subjects showed significant correlations with LVEF (r = -0.61, p < 0.001), PFR (r = -0.47, p < 0.01), LVEDV (r = 0.45, p < 0.01) and LVESV (r = 0.48, p < 0.01).
CONCLUSION: The myocardial washout rate of 99Tc-sestamibi is considered to be a novel marker for the diagnosis of myocardial damage in patients with chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126092     DOI: 10.1007/bf03000101

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  7 in total

1.  99 mTc-MIBI washout as a complementary factor in the evaluation of idiopathic dilated cardiomyopathy (IDCM) using myocardial perfusion imaging.

Authors:  Mohammad Kazem Shiroodi; Babak Shafiei; Nastaran Baharfard; Mohammad Esmail Gheidari; Babak Nazari; Elaheh Pirayesh; Ali Kiasat; Samaneh Hoseinzadeh; Abolghassem Hashemi; Mohammad Ali Akbarzadeh; Hamid Javadi; Iraj Nabipour; Majid Assadi
Journal:  Int J Cardiovasc Imaging       Date:  2010-12-28       Impact factor: 2.357

2.  A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies.

Authors:  Shinro Matsuo; Ichiro Nakae; Takayoshi Tsutamoto; Noriake Okamoto; Minoru Horie
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

3.  Methods of calculating 123I-β-methyl-P-iodophenyl-pentadecanoic acid washout rates in triglyceride deposit cardiomyovasculopathy.

Authors:  Zhuoqing Chen; Kenichi Nakajima; Ken-Ichi Hirano; Takashi Kamiya; Shohei Yoshida; Shintaro Saito; Seigo Kinuya
Journal:  Ann Nucl Med       Date:  2022-09-25       Impact factor: 2.258

4.  Usefulness of Tc-99m methoxyisobutylisonitrile scintigraphy for evaluating congestive heart failure.

Authors:  Tomonori Sugiura; Hiroyuki Takase; Takayuki Toriyama; Takatoshi Goto; Ryuzo Ueda; Yasuaki Dohi
Journal:  J Nucl Cardiol       Date:  2006 Jan-Feb       Impact factor: 5.952

5.  A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy.

Authors:  Gian Piero Carboni
Journal:  Am J Cardiovasc Dis       Date:  2012-10-25

6.  Significance of 99mTc-sestamibi myocardial scintigraphy after percutaneous coronary intervention in patients with acute myocardial infarction.

Authors:  Yoshihiro J Akashi; Kohei Ashikaga; Makoto Takano; Masaki Izumo; Yuki Ishibashi; Keisuke Kida; Kihei Yoneyama; Kengo Suzuki; Fumihiko Miyake; Maciej Banach
Journal:  Med Sci Monit       Date:  2011-02-25

7.  (99m)Tc-MIBI Washout Rate to Evaluate the Effects of Steroid Therapy in Cardiac Sarcoidosis.

Authors:  Masayoshi Sarai; Sadako Motoyama; Yasuchika Kato; Hideki Kawai; Hajime Ito; Kayoko Takada; Ryuji Yoda; Hiroshi Toyama; Shin-Ichiro Morimoto; Yukio Ozaki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.